🔍

BETA - Beta Drugs Ltd

📊 NSE: BETA 🏢 Pharmaceuticals - Indian - Bulk Drugs 📅 Last Updated: 12/13/2025 19:21

📢 Recent Corporate Announcements

Beta Drugs Allots 2.83 Lakh Shares at ₹1712.49 for Nivian Lifesciences Acquisition

🟢 POSITIVE ⭐ 8/10

M&A 📅 25 Apr 2026, 01:59 PM

Beta Drugs Limited has approved the allotment of 2,83,668 equity shares as part of its acquisition of Nivian Lifesciences Private Limited. The shares are being issued at a price of ₹1712.49 each, which includes a substantial premium of ₹1702.49 per share. This equity-based acquisition strategy allows the company to expand its portfolio while utilizing its stock as currency. The board finalized this decision in its meeting held on April 25, 2026.

Allotment of 2,83,668 equity shares to acquire Nivian Lifesciences Private Limited.
Issue price of ₹1712.49 per share, featuring a premium of ₹1702.49.
Face value of the newly issued shares is ₹10 per share.
The board meeting concluded on April 25, 2026, after nearly three hours of deliberation.

💡 Investors should evaluate the strategic fit of Nivian Lifesciences and monitor the impact on future EPS due to equity dilution. The high premium pricing reflects management's confidence in the company's current market valuation.

Beta Drugs Expands Global Footprint with Regulatory Milestones in Azerbaijan and Philippines

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 22 Apr 2026, 09:00 AM

Beta Drugs Limited has achieved significant regulatory progress, completing a successful GMP inspection by Azerbaijan's Ministry of Health with final approval expected within 1-2 months. In the Philippines, the company secured Certificates of Product Registration for 2 brands, representing the first generic versions of these products in that market. These developments are part of a broader strategy to penetrate the CIS and Southeast Asian markets, including Vietnam and Thailand. Furthermore, the company has triggered an EU GMP inspection, signaling an intent to enter highly regulated European markets.

Successful Azerbaijan Ministry of Health inspection conducted from April 13-17, 2026, with GMP approval expected in 1-2 months.
Secured Certificates of Product Registration (CPR) for 2 brands in the Philippines as the first generic approvals in that market.
Anticipates additional product approvals in the Philippines within the next 6 months to facilitate entry into Vietnam and Thailand.
Triggered EU GMP inspection to build upon existing approvals from PIC/S, ANVISA, INVIMA, and EAEU.

💡 Investors should monitor the conversion of these regulatory approvals into export revenue growth over the next 2-4 quarters. The successful trigger of an EU GMP inspection is a significant qualitative milestone that could re-rate the stock if successful.

Beta Drugs Limited Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Mar 2026, 10:43 AM

Beta Drugs Limited has informed the National Stock Exchange that its trading window will be closed starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of the audited financial results for the year ending March 31, 2026. The restriction applies to all directors, officers, and designated employees. The window is scheduled to reopen 48 hours after the financial results are officially announced.

Trading window closure effective from April 1, 2026.
Closure is related to the finalization of Audited Financial Results for FY 2025-26.
Restriction covers Directors, Officers, and Designated Employees under the company's insider trading code.
Trading window will reopen 48 hours after the results are declared to the exchange.

💡 No action is required as this is a routine regulatory filing. Investors should wait for the announcement of the audited financial results to assess the company's performance.

Beta Drugs Clarifies Post-Preferential Offer Shareholding for 33 Allottees

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 20 Mar 2026, 10:09 AM

Beta Drugs Limited has provided a detailed clarification to the National Stock Exchange regarding its proposed preferential offer. The disclosure lists 33 allottees and their respective post-issue shareholding percentages to ensure regulatory compliance. The largest individual allocation in this list is to Anjali Ajit Deval, who will hold 1.1329% of the company's post-offer capital. This clarification follows a corrigendum to the Notice of the Extra Ordinary General Meeting originally dated January 9, 2026.

Disclosure of post-preferential offer capital for 33 specific allottees.
Anjali Ajit Deval emerges as the largest allottee in this list with 1,25,596 shares (1.1329%).
Kayadam Ramanathan Bharat and Neha Bagla to hold 0.4256% and 0.3087% respectively post-allotment.
The list includes several institutional and individual investors with holdings ranging from 0.0018% to 1.1329%.

💡 Investors should note the progress of the preferential fundraise and the resulting equity dilution. Monitor the final allotment and the company's stated purpose for the raised capital.

Beta Drugs Clarifies Nivian Lifesciences Acquisition and 10% Equity Dilution

🟢 POSITIVE ⭐ 8/10

M&A 📅 16 Mar 2026, 04:22 PM

Beta Drugs Limited has provided detailed clarifications regarding its acquisition of Nivian Lifesciences and the associated preferential issue. The transaction involves a share swap ratio of 37 Beta shares for every 100 Nivian shares, alongside a cash consideration totaling approximately ₹20.82 crore. Post-issue, the promoter holding will dilute from 64.90% to 59.10%, while institutional investor participation is set to rise significantly from 3.03% to 9.14%. The total share capital will expand to 1.11 crore shares to facilitate this inorganic growth.

Promoter shareholding to dilute from 64.90% to 59.10% post-preferential issue.
Institutional investor stake to increase substantially from 3.03% to 9.14%.
Acquisition involves a share swap of 2,83,668 Beta shares at a 37:100 ratio.
Total cash consideration for the acquisition components is approximately ₹20.82 crore.
Total equity base to expand from 1,00,94,553 to 1,10,85,872 shares.

💡 Investors should view the increased institutional interest as a positive sign, but should monitor how the Nivian Lifesciences acquisition contributes to earnings to offset the ~10% equity dilution.

Beta Drugs Reports Zero Deviation in Utilization of ₹117 Crore Preferential Issue Proceeds

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 14 Feb 2026, 02:01 PM

Beta Drugs Limited has confirmed that there is no deviation or variation in the use of proceeds from its ₹117.01 crore preferential issue raised in November 2024. As of December 31, 2025, the company has utilized ₹20.78 crore towards its stated objectives, including facility upgrades and R&D. The monitoring agency, Brickwork Ratings, and the company's Audit Committee have reviewed and approved the utilization report. Significant funds remain unutilized for planned capital expenditure and geographical expansion, indicating ongoing project execution.

Total amount raised via preferential issue was ₹11,701.45 lakhs on November 25, 2024.
Cumulative funds utilized as of December 31, 2025, stand at ₹2,078 lakhs.
₹952 lakhs spent on new manufacturing setup out of a total allocation of ₹4,400 lakhs.
Zero utilization reported so far for geographical expansion (₹1,000 lakhs) and capital acquisitions (₹2,000 lakhs).
Monitoring agency Brickwork Ratings confirmed zero deviation from the original objects of the issue.

💡 Investors should track the deployment of the remaining ₹96 crore, particularly in high-growth areas like R&D and geographical expansion. The current utilization rate is approximately 18%, suggesting that the impact of these investments on the bottom line will be realized in future quarters.

Beta Drugs Q3 Results: PAT at ₹8.51 Cr; FY26 Revenue Guidance Cut to ₹400 Cr

🔵 WATCH ⭐ 7/10

EARNINGS 📅 14 Feb 2026, 01:36 PM

Beta Drugs reported flat year-on-year revenue of ₹89.58 Crores for Q3 FY26, as a 33% surge in high-margin own branded sales was offset by a strategic exit from the low-margin CDMO Platin business. While gross margins improved significantly to 59% from 52%, EBITDA margins remained stable at 22% due to increased hiring in regulatory and manufacturing teams. The company has revised its FY26 revenue guidance downward to ₹400 Crores from ₹420 Crores but set an ambitious FY27 target of ₹530 Crores. Net profit was impacted by rising interest costs, which climbed to ₹4.43 Crores due to CCD interest obligations.

Total Revenue stood flat at ₹89.58 Crores, while own branded sales grew strongly by 33% YoY.
Gross Margins saw a sharp increase to 59% in Q3FY26 compared to 52% in the previous year.
FY26 revenue outlook revised downward to ₹400 Crores due to the strategic de-focus on the Platin segment.
Interest expenses rose to ₹4.43 Crores from ₹1.87 Crores YoY, primarily on account of interest on CCDs.
Management projects FY27 revenue of ₹530 Crores with 24% EBITDA margins, driven by NDDS product launches.

💡 Investors should focus on the company's successful transition toward higher-margin own brands and NDDS products despite the short-term revenue stagnation. Monitor the execution of the FY27 growth targets and the impact of geopolitical tensions on export recovery.

Beta Drugs Revises Valuation Report for Nivian Life Sciences Acquisition Using Consolidated Data

🟡 NEUTRAL ⭐ 7/10

M&A 📅 12 Feb 2026, 10:43 AM

Beta Drugs Limited has announced a revision to the valuation report prepared for its proposed acquisition of Nivian Life Sciences Private Limited via a preferential issue. The registered valuer, Mr. Hitesh Jhamb, updated the report to use consolidated financial statements instead of the standalone figures used previously. This adjustment was made to provide a more comprehensive financial position under the Income and Cost approaches. The revised report, dated January 8, 2026, is now available for public inspection on the company's website.

Revision of valuation report for the acquisition of Nivian Life Sciences Private Limited
Shift from standalone to consolidated financial statements for valuation methodology
Valuation updated for both Income Approach and Cost Approach metrics
Revised report dated January 8, 2026, replaces the previous version for the preferential issue
Disclosure made under Regulation 30 of SEBI LODR Regulations

💡 Investors should review the revised valuation report on the company website to see if the shift to consolidated financials impacts the final issue price or dilution. Monitor for further updates on the approval of the preferential issue.

Beta Drugs Shareholders Approve Preferential Issue of 2.84 Lakh Shares at ₹1,712.49

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 04 Feb 2026, 03:47 PM

Beta Drugs Limited held an Extraordinary General Meeting on February 4, 2026, where shareholders unanimously approved all proposed resolutions. A key outcome is the approval of a preferential issue of 2,83,668 equity shares at a price of ₹1,712.49 per share, which includes a significant premium of ₹1,702.49. Additionally, the company received approval for its Employee Stock Option Plan (ESOP) 2026 and an increase in authorized share capital. These moves indicate a focus on capital infusion and talent retention through equity-based incentives.

Unanimous approval (100% in favor) for the issuance of 2,83,668 equity shares on a preferential basis.
Preferential issue price set at ₹1,712.49 per share, featuring a premium of ₹1,702.49 over the ₹10 face value.
Approval of the 'Beta Drugs Limited Employee Stock Option Plan 2026' for both company and group employees.
Authorized share capital increased and Memorandum of Association altered to facilitate the new share issuance.
Total of 5,969,737 valid votes were cast across all resolutions with zero votes against.

💡 Investors should view the successful fundraising at a high premium as a positive sign of valuation confidence. Monitor the specific use of proceeds from the preferential issue and the long-term impact of the ESOP on employee retention and equity dilution.

Beta Drugs Approves ₹48.58 Cr Fundraise via Preferential Issue and New ESOP 2026 Plan

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 04 Feb 2026, 12:23 PM

Beta Drugs Limited held an Extraordinary General Meeting on February 04, 2026, where shareholders approved a significant fundraise through a preferential issue. The company will issue 2,83,668 equity shares at a price of ₹1712.49 per share, including a premium of ₹1702.49, totaling approximately ₹48.58 crore. Additionally, the 'Beta Drugs Limited Employee Stock Option Plan 2026' was approved to incentivize employees across the group and subsidiaries. These moves are supported by an increase in the company's Authorized Share Capital to facilitate the new issuances.

Approved preferential issue of 2,83,668 equity shares at a price of ₹1712.49 per share
Total capital infusion through the preferential offer amounts to approximately ₹48.58 crore
Launch of 'Employee Stock Option Plan 2026' for employees of the company and its group entities
Increase in Authorized Share Capital and alteration of the Memorandum of Association approved
Preferential issue price includes a significant premium of ₹1702.49 over the ₹10 face value

💡 Investors should view the fundraise at a high premium as a sign of strong valuation support and confidence from specific investors. Monitor the company's upcoming disclosures regarding the specific utilization of these funds for expansion or debt reduction.

Beta Drugs to Acquire Nivian Lifesciences Stake via INR 48.57 Cr Share Swap; Proposes ESOP 2026

🟢 POSITIVE ⭐ 8/10

M&A 📅 12 Jan 2026, 06:33 PM

Beta Drugs Limited has scheduled an EGM for February 4, 2026, to approve a strategic acquisition of Nivian Lifesciences Private Limited via a share swap arrangement. The company will issue 2,83,668 equity shares at a price of INR 1,712.49 per share to the sellers of the target company, representing a total value of approximately INR 48.57 crore. Additionally, the board has proposed an ESOP 2026 scheme for 2,00,000 shares (1.98% of paid-up capital) to incentivize employees. To facilitate these issuances, the authorized share capital is being raised from INR 11 crore to INR 11.40 crore.

Issuance of 2,83,668 shares at INR 1,712.49 each for a non-cash consideration (share swap) to acquire Nivian Lifesciences
Proposed ESOP 2026 plan involving 2,00,000 shares, representing 1.98% of the paid-up equity as of March 2025
Authorized share capital to be increased from INR 11,00,00,000 to INR 11,40,00,000
Acquisition involves key allottees including Anjali Ajit Deval and Kayadam Ramanathan Bharat
The issue price includes a substantial premium of INR 1,702.49 per share over the face value of INR 10

💡 Investors should monitor the integration and growth potential of Nivian Lifesciences to justify the share dilution. The high issue price indicates strong internal valuation and confidence in the company's growth trajectory.

Beta Drugs to Acquire 66.09% Stake in Nivian Lifesciences for INR 69.4 Crores

🟢 POSITIVE ⭐ 9/10

M&A 📅 11 Jan 2026, 10:20 AM

Beta Drugs Limited has entered into a definitive agreement to acquire a 66.09% stake in Nivian Lifesciences, a fast-growing player in the In-Vitro Fertilisation (IVF) segment. The acquisition is valued at INR 69.4 Crores, implying a total valuation of INR 105 Crores for Nivian. Nivian reported net sales of INR 30.30 Crores for the 9 months ended December 2025 and is projected to reach approximately INR 43 Crores by the end of FY26. This strategic move allows Beta Drugs to diversify its portfolio into the high-growth women's health and fertility market, which is currently expanding at a 20% CAGR.

Acquisition of 66.09% stake in Nivian Lifesciences for INR 69.4 Crores, valuing the company at INR 105 Crores.
Nivian reported 9M Dec'25 net sales of INR 30.30 Crores with a FY26 revenue target of ~INR 43 Crores.
Entry into the IVF therapy market, which has a total addressable size of INR 1,500-1,700 Crores in India.
Strategic synergy combining Beta's manufacturing capabilities with Nivian's marketing expertise in niche formulations.
Founder Nilesh Auti will continue to lead Nivian's operations and remain a minority shareholder.

💡 Investors should look favorably on this acquisition as it provides Beta Drugs entry into a high-margin, high-growth niche segment. Monitor the post-acquisition integration and the impact on consolidated earnings in the coming fiscal year.

Beta Drugs to Acquire 66.09% Stake in Nivian Lifesciences for INR 69.4 Crores

🟢 POSITIVE ⭐ 9/10

M&A 📅 10 Jan 2026, 06:45 PM

Beta Drugs Limited has signed a definitive agreement to acquire a 66.09% majority stake in Nivian Lifesciences, valuing the target at INR 105 Crores. Nivian is a high-growth player in the In-Vitro Fertilisation (IVF) segment, which has experienced a 20% CAGR over the last five years. Nivian reported net sales of INR 30.30 Crores for the nine months ending December 2026 and expects to close FY27 at approximately INR 43 Crores. This acquisition enables Beta Drugs to diversify its portfolio into women's health and fertility, complementing its existing strengths in oncology and cosmetology.

Acquisition of 66.09% stake for INR 69.4 Crores, implying a total valuation of INR 105 Crores for Nivian.
Nivian projects FY27 revenue of ~INR 43 Crores, following a strong 9M performance of INR 30.30 Crores.
Entry into the IVF therapy market, which has an estimated total market size of INR 1,500-1,700 Crores.
Strategic synergy combines Beta's manufacturing cost leadership with Nivian's specialized IVF marketing and sales expertise.
Founder Nilesh Auti will continue to lead Nivian's operations, ensuring management continuity and expertise retention.

💡 Investors should look favorably on this acquisition as it provides Beta Drugs with a high-growth vertical outside of oncology. Monitor the post-acquisition integration and the impact on consolidated EBITDA margins in the coming fiscal year.

Beta Drugs to Acquire 66.09% Stake in Nivian Life Sciences for ₹69.40 Crores

🟢 POSITIVE ⭐ 9/10

M&A 📅 09 Jan 2026, 05:15 PM

Beta Drugs has approved the acquisition of a 66.09% majority stake in Nivian Life Sciences, a specialist in the high-growth In-Vitro Fertilisation (IVF) therapy segment. The total consideration of ₹69.40 crores will be settled through a mix of ₹20.82 crores in cash and ₹48.58 crores via a share swap, issuing 2,83,668 shares at ₹1,712.49 per share. Nivian reported a turnover of ₹29.12 crores and an EBITDA of ₹4.22 crores for FY25. The board also approved a new ESOP scheme for 2,00,000 shares and an increase in authorized share capital.

Acquisition of 66.09% stake in Nivian Life Sciences for a total value of ₹69.40 Crores
Consideration includes ₹20.82 Cr cash and issuance of 2,83,668 equity shares at ₹1,712.49 each
Target entity Nivian Life Sciences achieved FY25 turnover of ₹29.12 Cr and EBITDA of ₹4.22 Cr
Implementation of 'ESOP 2026' plan covering up to 2,00,000 equity shares for employees
Authorized share capital increased from ₹11.00 Cr to ₹11.40 Cr to facilitate the share swap

💡 Investors should monitor the integration of Nivian's IVF portfolio, which offers high-growth synergies with Beta's existing oncology distribution network. The acquisition valuation at approximately 16.4x EBITDA appears strategic for entry into a niche pharmaceutical segment.

Beta Drugs Limited Submits Routine SEBI Compliance Certificate for Q2 FY2025-26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 01:43 PM

Beta Drugs Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, covers the quarter ended September 30, 2025. Notably, the registrar reported that no requests for dematerialization were received from shareholders during this specific period. This filing is a standard administrative procedure to confirm that the company's register of members is accurately maintained in accordance with depository records.

Submission of compliance certificate under Regulation 74(5) for the quarter ended September 30, 2025.
Registrar MUFG Intime India confirmed that 0 dematerialization requests were received during the quarter.
The document confirms that the company is in compliance with SEBI's prescribed timelines for security processing.
The filing ensures that the name of depositories is correctly substituted in the register of members for any processed securities.

💡 No action is required from investors as this is a routine regulatory filing that does not impact the company's financial health or operations.

View All BETA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 13% YoY to INR 203.6 Cr in H1 FY26. Segment growth: Domestic Own Brands grew 21% YoY (INR 69.4 Cr), CDMO grew 8% YoY (INR 79 Cr), International/Exports grew 10% YoY (INR 43.2 Cr), and API external sales grew 14% YoY (INR 12.25 Cr).

Geographic Revenue Split

Domestic sales (including Branded and CDMO) contribute approximately 73% of total revenue, while International/Export markets contribute 21%. The remaining 6% is derived from API sales.

Profitability Margins

Gross margins decreased by 1.5% to 51.35% in H1 FY26 due to product mix shifts. Operating margins are projected to remain between 20-22% through FY26. Branded business yields high EBITDA margins of 35-36%, while CDMO margins are lower at 16-17%.

EBITDA Margin

EBITDA margin improved to 23.08% in H1 FY26 from 22.36% in H1 FY25, a YoY increase of 72 bps. Excluding the newly break-even Derma division, core EBITDA margins stand higher at 24.12%.

Capital Expenditure

Net fixed assets increased from INR 88.93 Cr in FY25 to INR 111.52 Cr in H1 FY26, reflecting ongoing investments in machinery at the Adley plant and regulatory upgrades at the Beta plant.

Credit Rating & Borrowing

CRISIL BBB+/Stable. The company maintains low reliance on external debt with a gearing ratio of 0.07x as of March 2024. Interest coverage is robust at 11.26x in H1 FY26.

⚙️ Operational Drivers

Raw Materials

Oncology APIs and Platin group compounds. Platin group products represent a segment where margins are significantly lower (10-15% GC) compared to innovative products (50-70% GC).

Capacity Expansion

The company has added significant machinery and capacity at the Adley Formulation plant to handle 100% of domestic branded and CDMO production. The Beta standalone plant is being repurposed exclusively for regulated export markets.

Raw Material Costs

Raw material costs are subject to price volatility, particularly in the Platin group. Management utilizes a pass-through pricing strategy for own-branded products to mitigate margin erosion from input cost spikes.

Manufacturing Efficiency

RoCE was healthy at 37.2% in FY22 and is estimated to remain around 37% in FY24, driven by economies of scale and integrated in-house operations.

Logistics & Distribution

Distribution is supported by a strong sales network and diversified clientele including large government and private hospitals.

📈 Strategic Growth

Expected Growth Rate

20-25%

Growth Strategy

Shifting the Beta standalone plant to serve regulated markets (Mexico, South Africa, Vietnam) with 11 identified high-margin products. Doubling the regulatory team to file 150+ dossiers over the next two years and launching two new NDDS (New Drug Delivery Systems) products.

Products & Services

Oncology products (anti-cancer tablets), Dermatology products, and Oncology APIs.

Brand Portfolio

Not disclosed in available documents, though 6 brands are expected to reach INR 5 Cr in annual sales each.

New Products/Services

Launch of Methotrexate and two NDDS molecules expected to drive growth in H2 FY26 and beyond.

Market Expansion

Targeting regulated markets with 16 dossiers filed in Mexico, 4 in South Africa, and multiple filings in Algeria and Vietnam.

Strategic Alliances

Maintains CDMO relationships with major pharmaceutical companies; specific partner names not disclosed.

🌍 External Factors

Industry Trends

The oncology market is shifting toward regulated market compliance and complex delivery systems. Beta is positioning itself by upgrading plants for international audits (Mexico/Colombia) and developing NDDS molecules.

Competitive Landscape

Faces intense competition in the CDMO and branded generics space from both domestic and international pharmaceutical players.

Competitive Moat

Moat is built on specialized oncology manufacturing and backward integration into APIs, which is sustainable due to high entry barriers in cytotoxic (anti-cancer) drug production.

Macro Economic Sensitivity

Sensitive to healthcare spending and government tender cycles, particularly in the export segment which is largely tender-driven.

Consumer Behavior

Increasing prescriber base (up 8% in H1 FY26) indicates growing doctor acceptance of Beta's oncology brands.

Geopolitical Risks

Trade barriers or regulatory hurdles in target export geographies like Colombia and the Philippines could impact the planned 150+ dossier filings.

⚖️ Regulatory & Governance

Industry Regulations

Subject to stringent WHO-GMP and international regulatory audits (COFEPRIS Mexico, INVIMA Colombia). Successful completion of audits in H1 FY26 with no critical observations.